Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Operating expenses:
Research and development	$ 454,907	$ 587,240	$ 955,080	$ 1,090,791
Clinical and regulatory	1,321,418	3,373,758	4,479,253	5,543,231
General and administrative	1,083,298	893,242	2,114,456	2,202,398
Total operating expenses	2,859,623	4,854,240	7,548,789	8,836,420
Loss from operations	(2,859,623)	(4,854,240)	(7,548,789)	(8,836,420)
Interest income	7,854	20,702	18,955	29,828
Other (expense) income, net	(57,166)	3,865	22,535	25,482
Interest expense	(123,832)	(73,075)	(259,954)	(148,505)
Total non-operating (expenses) income, net	(173,144)	(48,508)	(218,464)	(93,195)
Net loss	(3,032,767)	(4,902,748)	(7,767,253)	(8,929,615)
Net loss - non-controlling interest	(107,546)	(189,277)	(282,428)	(306,946)
Net loss attributable to Heat Biologics, Inc.	$ (2,925,221)	$ (4,713,471)	$ (7,484,825)	$ (8,622,669)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted	$ (0.17)	$ (0.56)	$ (0.56)	$ (1.13)
Weighted-average number of common shares used in net loss per share attributable to common stockholders - basic and diluted	17,524,641	8,401,159	13,324,641	7,612,393
Other comprehensive loss:
Net loss	$ (3,032,767)	$ (4,902,748)	$ (7,767,253)	$ (8,929,615)
Unrealized gain/(loss) on foreign currency translation	49,233	(16,185)	(26,574)	(37,051)
Total other comprehensive loss	(2,983,534)	(4,918,933)	(7,793,827)	(8,966,666)
Comprehensive loss attributable to non-controlling interest	(107,546)	(189,277)	(282,428)	(306,946)
Comprehensive loss	$ (2,875,988)	$ (4,729,656)	$ (7,511,399)	$ (8,659,720)